J. Nicholas Bodor, MD, PhD, MPH

Dr. J.N. Bodor
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Assistant Professor, Department of Hematology/Oncology

Thoracic Oncology Program


  • Thoracic Medical Oncology

Areas of Expertise

Lung Metastases, Lung Cancer

Treatment Focus

  • Non-small cell lung cancer (NSCLC)
  • Lung cancer among individuals who have never smoked
  • EGFR-mutated Non-small lung cancer


Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427

Educational Background

  • Hematology and Oncology Fellowship, Fox Chase Cancer Center - Temple University Hospital Philadelphia, PA, 2017-20
  • Internal Medicine Residency, University of Maryland Medical Center, Department of Medicine Baltimore, MD, 2014-17
  • MD, Louisiana State University, School of Medicine New Orleans, LA, 2014
  • Postdoctoral Fellowship, Tulane University, School of Public Health and Tropical Medicine New Orleans, LA, 2009-10
  • PhD, Public Health Nutrition, Tulane University, School of Public Health and Tropical Medicine New Orleans, LA, 2009
  • MPH, Maternal and Child Health/Epidemiology, Tulane University, School of Public Health and Tropical Medicine New Orleans, LA, 2003


  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology


  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • International Association for the Study of Lung Cancer

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2024
  • ASCO Annual Meeting Merit Award American Society of Clinical Oncology Chicago, IL, 2018

Selected Publications

  1. O'Brien J, Bodor JN. Perioperative Immunotherapy in Non-Small Cell Lung Cancer. Curr Treat Options in Oncol. 2023 Dec 13. Online ahead of print.
  2. Bodor JN, Patel JC, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Phase II Randomized trial of carboplatin, pemetrexed, and bevacizumab with and without atezolizumab in stage IV non-squamous non-small cell lung cancer patients who harbor a sensitizing EGFR mutation or have never smoked. Clin Lung Cancer. 2023 24(7); e242-e246
  3. Bodor JN, Bauman JR, HandorfEA, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-LI and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Cancer Res Clin Oncol. 2023 149(5):1755-1763.
  4. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 12(25):2449-2458.
  5. Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF. Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLHl, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden {TMB) in 1,057 microsatellite instability-high solid tumors. Int J Cancer. 2020 May 24. doi: 10.1002/ijc.33l l 5.
  6. Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020 126:260-270.
  7. Bodor JN, Feliciano JL, Edelman MJ. Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation. Lung Cancer 2019 135:16-20
  8. Bodor JN, Kasireddy V, Borghaei H. First-line therapies for metastatic lung adenocarcinoma without a driver mutation. J Oncol Pract. 2018 Sep;14:529-535.
  9. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018; 10 (Suppl 3):S480-S489.
  10. Bodor JN, Hutchison PL, Rose D. Car ownership and the association between fruit and vegetable availability and diet. Preventive Medicine 2013;57:903-905.
  11. Bodor JN, Rice JC, Farley TA, Swaim CM, Rose D. The association between obesity and urban food environments. Journal of Urban Health 2010;87:771-81.
  12. Bodor JN, Rice JC, Farley TA, Swaim CM, Rose D. Disparities in food access: Does aggregate availability of key foods from other stores offset the relative lack of supermarkets in African-American neighborhoods? Preventive Medicine 2010;51:63-7.

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...